Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) Other Operating Expenses (2018 - 2023)

Exagen filings provide 6 years of Other Operating Expenses readings, the most recent being -$17.5 million for Q4 2023.

  • On a quarterly basis, Other Operating Expenses fell 247.88% to -$17.5 million in Q4 2023 year-over-year; TTM through Sep 2024 was -$17.5 million, a 159.66% decrease, with the full-year FY2022 number at $29.7 million, up 44.36% from a year prior.
  • Other Operating Expenses hit -$17.5 million in Q4 2023 for Exagen, down from $5.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $11.8 million in Q4 2022 to a low of -$17.5 million in Q4 2023.
  • Median Other Operating Expenses over the past 5 years was $5.0 million (2019), compared with a mean of $4.3 million.
  • Biggest five-year swings in Other Operating Expenses: soared 139.22% in 2022 and later tumbled 247.88% in 2023.
  • Exagen's Other Operating Expenses stood at $4.6 million in 2019, then fell by 5.58% to $4.3 million in 2020, then rose by 13.93% to $4.9 million in 2021, then skyrocketed by 139.22% to $11.8 million in 2022, then tumbled by 247.88% to -$17.5 million in 2023.
  • The last three reported values for Other Operating Expenses were -$17.5 million (Q4 2023), $5.7 million (Q3 2023), and $5.8 million (Q2 2023) per Business Quant data.